key: cord-0703479-miosb9sz
authors: Sakuraba, Atsushi; Luna, Alexander; Micic, Dejan
title: Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis
date: 2021-09-29
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.09.055
sha: caf264b5218fa0f79a0a7bb73b29a14b1ecfaac6
doc_id: 703479
cord_uid: miosb9sz

Background and aims Patients with immune-mediated inflammatory diseases (IMIDs) have an increased risk of COVID-19, primarily attributed to the use of immunosuppressive drugs such as glucocorticoids, which may attenuate the response to vaccines. This meta-analysis aims to assess the serologic response to COVID-19 vaccination in patients with IMIDs. Methods Electronic databases were searched on August 1, 2021 for observational studies. Data including reference population, medications, vaccination, and proportion of patients achieving a serologic response were extracted. Results Twenty-five observational studies (5360 patients) were included for analyses. A majority of the studies used mRNA vaccines (BNT162b2, mRNA-1273) with a small number of studies including other types of vaccines (AZD1222, Coronavac, BBV152, Ad26.COV2.S). Serologic response after a single (6 studies) and two doses (17 studies) of mRNA vaccine were 73.2% (95% confidence interval [CI] 65.7-79.5) and 83.4% (95%CI 76.8-88.4), respectively. On meta-regression, anti-CD20 therapy was associated with lower response rates (P <0.001) and anti-TNF therapy also showed a trend toward lower response rates (P = 0.058). Patients with IMIDs were less likely to achieve a serologic response compared to controls after two doses of mRNA vaccine (6 studies; odds ratio 0.086, 95% CI 0.036-0.206, P < .001). There were not enough studies to assess response to the adenoviral or inactivated vaccines. Conclusions Our meta-analysis demonstrated that patients with IMIDs have a reduced response to mRNA COVID-19 vaccines. These results suggest that IMID patients receiving mRNA vaccines should complete the vaccine series without delay and support the strategy of providing a 3rd dose of the vaccine.

A novel RNA coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic and global health emergency. 1 Patients with preexisting conditions such as immune-mediated inflammatory diseases (IMIDs) may be more susceptible to getting infected with SARS-CoV-2 and there is concern that certain immunosuppressive therapies may lead to worse outcomes. 2, 3 To understand the incidence and prognosis of COVID-19 in IMIDs, international registries of patients with inflammatory bowel disease (SECURE-IBD registry) or rheumatic diseases (C19-GRA) diagnosed with were developed and analyzed with respect to individual patient outcomes. 4 These studies have demonstrated that similar to the general population, age and underlying comorbidities were poor prognostic factors among patients with IMIDs developing COVID-19. 5, 6 We have previously reported in a meta-analysis that included 62 studies, that the prevalence of COVID-19 was elevated in rheumatic diseases. 3 Studies in IBD suggest that the risk is similar to the general population. 7 With respect to the therapies often used in the management of patients with IMIDs, glucocorticoids (GCs), csDMARDs (conventional synthetic disease-modifying antirheumatic drugs) and b/ts (biological/targeted synthetic) DMARDs-csDMARDs combination therapy significantly increased the risk of severe outcomes, whereas b/tsDMARDs monotherapy, in particular anti-tumor necrosis factor (TNF) therapy, reduced the risk of severe With the lack of effective treatments, prevention strategies including vaccination are of paramount importance in reducing the risk of COVID-19. 8 Rapidly emerging data has shown that mRNA-based COVID-19 vaccines are safe and effective in the general population. However, the efficacy of COVID-19 vaccines in patients with IMIDs is unknown as patients with IMIDs or those treated with immunosuppressing therapies were excluded from regulatory vaccine trials. 9 Guidelines currently recommend that patients with IMIDs should be vaccinated against SARS-CoV-2 due to the ongoing pandemic and risk of mortality. 10, 11 Data from other vaccine-preventable illnesses suggest attenuated responses in patients receiving glucocorticoids (GCs), TNF antagonists and immunosuppressive drugs such as cyclophosphamide and azathioprine. 10, 12 A recent study by Kennedy et al. reported that inflammatory bowel disease (IBD) patients receiving infliximab had an attenuated immunogenicity to a single-dose of the BNT162b2 and J o u r n a l P r e -p r o o f 5 ChAdOx1 nCoV-19/AZD1222 SARS-CoV-2 vaccines compared to those receiving vedolizumab, a gut-selective biologic. 13 Additional studies investigating the effectiveness of COVID-19 vaccines in IMIDs are limited and mostly include small sample sizes. Therefore, there is a need to integrate findings across studies to better understand the effectiveness of COVID-19 vaccines in patients with IMIDs. In this systematic review and meta-analysis, our aim was to determine the serologic response rate to COVID-19 vaccination in patients with IMIDs.

This meta-analysis was conducted according to a priori defined protocol that is in accordance with the PRISMA guideline. 14 The protocol of this meta-analysis has been submitted to the International Prospective Register of Systematic Reviews (PROSPERO). 15 We searched PubMed/MEDLINE, EMBASE, and medRxiv (https://www.medrxiv.org/) from inception to August 1, 2021 to identify studies assessing the response to COVID-19 vaccination in patients with IMIDs.

As for inclusion criteria, we considered observational studies reporting the outcomes of COVID-19 vaccination in IMIDs patients. There were no restrictions regarding age, sex or duration of the study. We imposed no geographic or language restrictions. Two authors (AL, AS) independently screened each of the potential studies to determine whether they were eligible for inclusion. Areas of disagreement or uncertainty were resolved by consensus among the authors. Studies were identified with the following terms: "COVID-19", "SARS-CoV-2", "vaccine", ''immunization", "inflammatory bowel diseases" OR "rheumatoid arthritis" OR "psoriasis" OR "rheumatic diseases"

OR "systemic lupus erythematosus", "psoriatic arthritis", "ankylosing spondylitis", "Crohn's disease", "ulcerative colitis" OR "multiple sclerosis", "immune mediated diseases" OR "autoimmune diseases". A search was also 7 used a different serologic testing method. When tests were performed at multiple time points in a study, we chose the date closest to 4 weeks after the vaccination.

To conduct subgroup analyses with each disease, we classified IMIDs based on the target organ, i.e., digestive, musculoskeletal, urinary (kidney), and integumentary systems. Diseases of the digestive system were categorized into IBD. Rheumatic diseases included rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriatic arthritis, spondyloarthritis, ankylosing spondylitis, vasculitis, polymyalgia rheumatica, Sjögren's syndrome (SjS), systemic sclerosis (SSc) and other autoimmune-mediated diseases (including Behcet's disease, sarcoidosis, vasculitis, and inflammatory myopathies). Diseases of the skin were categorized as psoriasis/autoimmune skin diseases.

Immune mediated kidney diseases included ANCA-associated vasculitis, minimal change disease/focal and segmental glomerulosclerosis, and membranous nephropathy. Studies that included various IMIDs were classified as mixed group.

Subgroup analyses or meta-regression according to type of vaccine, age, disease, or medication use were undertaken when data were available.

We undertook a meta-analysis of the rate of serologic response to COVID-19 vaccination among individuals with IMIDs from observational studies by using a random effects model. Inverse variance of each study's effect estimator was used to allocate the weight to each study in the synthesis. The presence of heterogeneity across studies was assessed by using the I 2 statistic. An I 2 value of <25% indicates low heterogeneity, 25-75% as moderate heterogeneity and >75% as considerable heterogeneity. 18 Heterogeneity was evaluated by using Cochran's Qstatistics with a significance level of P <0. 10. 19 Begg's and Egger's tests were performed to assess publication bias and funnel plots were constructed to visualize asymmetry when ≥3 studies were available. 20, 21 Univariate and multivariate meta-regression models were used to assess the contributions of each of potential risk factors and medication class to the outcome of vaccine response. Multivariate meta-regression was undertaken with the variables that had a P J o u r n a l P r e -p r o o f 8 <0.05 on univariate meta-regression. When the number of available studies for each analysis was less than 10, funnel plot construction and meta-regression analysis were undertaken for reference purpose due to its low reliability.

We included preprints because they form a substantial part of the available COVID-19 evidence, but due to their lack of peer-review, we conducted a sensitivity analysis by excluding preprints. 22 We also performed one study removed analyses to assess whether the results are strongly influenced by any single study. When comparing serologic response to controls, zero event studies were excluded from analysis, but we also performed sensitivity analysis including all studies by applying the standard continuity correction of 0.5 to zero event studies. 23 Statistical analyses were performed using the Comprehensive Meta Analysis Software (version 3; Biostat, Englewood, NJ, USA). All statistical tests except for the Q-statistics used a two-sided P value of .05 for significance.

Data will be made available upon request to the corresponding author. All authors had access to the study data and reviewed and approved the final manuscript.

We did not directly include patient and public involvement in this study. Patients were not invited to comment on the study design and were not consulted to interpret the results. Patients were not invited to contribute to the writing or editing of this manuscript.

We identified 1912 citations through the literature search, excluded 1825 titles and abstracts after initial screening, and assessed 87 studies for eligibility. Twenty-five articles including 5360 patients met eligibility criteria ( Figure 1 ). As shown in Table 1 , 12 were full-text articles, 13, 24-34 9 were correspondence/letters, 35-43 and 4 were preprints. 44 41, 45, 47 but data were not reported separately, so these studies were included in the analyses of mRNA vaccines. Two studies used CoronaVac (Sinovac) only. 31, 33 One study included patients who used BBV152 (Covaxin) and data was separately reported. 46 For the analyses on the rate of serologic response to COVID-19 vaccination, six and twenty studies were available for assessment after one 13, 25, 30, 36-38 and two 13, 24-29, 31-35, 39-44, 48, 49 doses, respectively. Nine studies compared outcomes after two doses to a control population without IMIDs, 27-29, 31-33, 44, 48, 49 but there was only one study that had a control population after one dose. 30 A majority of the studies that assessed serologic response after the first vaccination performed testing 2-3 weeks post-vaccination. In regards to studies that assessed serologic response after the second vaccination, most performed testing between 1-3 weeks post-vaccination. The summary of characteristics and outcomes of the included studies are summarized in Table 1 

There were eight studies (6 mRNA studies 25, 30, 36-38 and 2 AZD122 studies 37 ) that assessed the serologic response after the first dose of mRNA vaccine in patients with IMIDs. As shown in Figure 2A On multivariate meta-regression, a greater proportion of patients taking anti-TNF agents among studies was associated with lower serologic response rates (coefficient -2.60, 95%CI -4.49-(-0.72), P = .0069), which likely contributed to the difference in serologic response rates and overall heterogeneity (I 2 = 93.68%) (Supplementary Table 3 ). In regards to disease type, studies that included patients with IBD had a lower rate of serologic response compared to rheumatoid studies (49.2% vs 65.00%), which likely reflects the greater proportion of patients using anti-TNF agents in IBD studies. Funnel plot showed no publication bias (Begg's test P = .26, Egger's test P = 0.39) (Supplementary Figure 1) .

Sensitivity analyses were carried out to assess whether individual studies influenced the results Figure 2A) . When individual studies were removed one at a time from the analyses, the corresponding pooled rates were not markedly altered by any single study (rates ranging from 63.7-74.7%), confirming the stability of the results. Specifically, when the study with the largest sample size was removed, the result was similar. No preprint studies were included for this analysis, so sensitivity analysis excluding preprints was not performed.

Two studies assessed the serologic response after the first dose of AZD122 vaccine ( Figure 2B ). The pooled proportion of patients achieving a serologic response was 35.7% (95% confidence interval [CI] 32.3-39.3).

There were eighteen studies that assessed serologic response after two doses of mRNA vaccines. 24-29, 32, 34, 35, 39-44, 47, 48 As shown in Figure 3A , the pooled proportion of patients achieving a serologic response was 83.4% (95%CI 76.8-88.4). Heterogeneity was present (I 2 = 90.31%) and multivariate meta-regression showed that a greater proportion of patients taking anti-CD20 therapies was associated with lower serologic response rates (coefficient -6.08, 95%CI -9.40-(-2.76), P < .001). Older age was also associated with lower serologic response rates (coefficient -0.044, 95%CI -0.083-(-0.0050), P = .027), but the coefficient was very small. Anti-TNF agent use among studies was associated with numerically, but not statistically, lower serologic response rates (coefficient -3.19, 95%CI -6.48-0.10, J o u r n a l P r e -p r o o f 11 P = .058) (Supplementary Table 4 ). Funnel plot showed no publication bias (Begg's test P = .79, Egger's test P = .90) (Supplementary Figure 3A) . Figure 4A) . 44, 45, 47 Exclusion of preprints demonstrated a serologic response rate similar to when they were included (81.2% vs 83.4%).

Remove one study analysis also showed that pooled rates were not markedly altered by any single study (Supplementary Figure 4B) . 46 ) , Coronavac (two studies 31, 33 ), and BBV152 (one study 46 ), respectively. The low response rate seen with Coronavac is due to one study reporting a low rate at 28 days after the vaccination. 33 Interestingly, this study reported a higher response rate at 69 days after the vaccination.

Only one study 30 compared the serologic response to control patients after one dose of mRNA vaccine (odds ratio (OR) 0.099, 95% CI 0.006-1.73, P = .11) ( Figure 4A ). Figure 4B , meta-analysis of six studies 27-29, 32, 44, 45 that included control patients without IMIDs demonstrated that a significantly smaller proportion of patients with IMIDs achieved a serologic response compared to control patients after two doses of vaccine (OR 0.086, 95% CI 0.036-0.21, P< .001). A majority of the studies also reported lower levels of antibody titers or concentrations in patients with IMIDs compared to controls 24, 25, 27-29, 44, 45 ( Table 1) . Heterogeneity was absent (I 2 = 0%) and funnel plot showed no publication bias (Begg's test P = .71, Egger's test P = .16) (Supplementary Figure 5A) . Figure 6A) .

Exclusion of preprints demonstrated an OR similar to when they were included (0.061 vs 0.086). Remove one study analysis also showed that OR were not markedly altered by any single study (Supplementary Figure 6B) . When two J o u r n a l P r e -p r o o f studies with zero events were included in analysis, the results were similar (OR 0.10, 95% CI 0.044-0.23, P < .001) (Supplementary Figure 6B) .

There were only a small number of studies that compared the serologic response to controls after two doses of other types of vaccine ( Figure 4C-E) . The OR were 0.22 (95%CI 0.012-4.03, P = .31), 0.39 (95%CI 0.27-0.55, P < .001), and 0.38 (95%CI 0.080-1.82, P = .23) with AZD1222 (one study 46 ) , Coronavac (two studies 31, 33 ), and BBV152 (one study 46 ), respectively.

Based on the GRADE approach, an overall quality of evidence for this analysis was low as the data were obtained from observational studies (Supplementary Table 5 ).

In the present meta-analysis, we assessed the serologic responses to COVID-19 vaccination in patients with IMIDs. We demonstrated that a significantly lower proportion of patients with IMIDs (82.3%) achieved a serologic response to two doses of COVID-19 mRNA vaccines compared to control patients. The response after a single dose (73.2%) appeared to be lower than the rates reported in healthy controls in the literature, so patients with IMIDs should receive the complete vaccination series without delay. The lower serologic response to a two vaccine strategy for the mRNA-based vaccines suggests patients should be considered to receive a 3rd dose of the vaccination. There 52 The response rates reported in their study were similar to our study and they reported that the response was attenuated in patients with rheumatoid arthritis or those on anti-CD20 or anticytotoxic T lymphocyte associated antigen therapies suggesting the need of assessing seroconversion in these patients. The results of our subgroup analysis and multivariate meta-regression confirm their results, but we consider that the response rates in IMID patients are suboptimal that they should complete the vaccine series without delay and should be considered for a 3rd dose of the vaccine. There were only a few studies that included patients with ChAdOx1 nCoV-19/AZD1222 or other types of vaccine, so future studies will also need to include patients treated with different vaccines.

Only 8 months have passed since the UK first approved BNT162b2, so available studies in the patient population with IMIDs mostly included limited numbers of participants. There are currently 9 different vaccines on J o u r n a l P r e -p r o o f 14 the global market, but the included studies mostly used mRNA vaccines requiring two doses: either BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), so further research is needed whether the results of our study can be generalized to other vaccines. Most of the included studies only assessed humoral responses to vaccination, and the extent to which cell-mediated immunity is involved remains unclear. 53 Included studies were heterogeneous in regards to sample size, type of IMIDs, medication use, and type of and timing of antibody testing. We analyzed IMIDs together due to limited number of studies, but further research of the individual disease states is warranted as they consist of different age groups and are often treated with different types of biologics (anti-CD20 therapy, anti-TNF agents, anti-integrins, etc) which have different degree of influence on vaccine response. A small number of studies were preprints, but sensitivity analyses demonstrated that their exclusion did not influence the results. Despite some potential drawbacks, preprints have an increasing role in creating timely evidence during the current pandemic. 54 Furthermore, due to novel variants of SARS-CoV-2 and waning antibody response, effectiveness of or serologic response to COVID-19 vaccines may vary depending on the timing of testing. Research and knowledge of COVID-19 vaccine are rapidly evolving and updated living meta-analyses are warranted in the future.

This study is the first meta-analysis which analyzed the rate of seroconversion to COVID-19 vaccines in patients with IMIDs. Our meta-analysis demonstrated that 82.3% of patients with IMIDs achieved a serologic response to two doses of COVID-19 mRNA vaccines, which was statistically lower compared to controls. The results of our study suggest that patients with IMIDs should receive the series of mRNA vaccines without delay and be considered for the 3 rd dose of the vaccination. Further studies assessing the response to different types of vaccines is warranted. A. Sensitivity analysis excluding one study at a time for serologic response after one dose of mRNA vaccine A. Sensitivity analysis excluding preprints for comparison of serologic response after two doses of mRNA vaccine to controls Immune diseases Control Rheumatoid P < .001, Heterogeneity: I 2 = 0%, Q = 1.65, P = . 44 Mixed P = .029, Heterogeneity: I 2 = 0%, Q = 0, P = 1. 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Associations of baseline use of biologic or targeted synthetic DMARDs 16

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges

Antigen-specific antibody responses in lupus patients following immunization

The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

PROSPERO's progress and activities 2012/13

JBI Manual for Evidence Synthesis

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)

Measuring inconsistency in meta-analyses

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis

Immunogenicity of the ChAdOx1 nCoV-19 and the BBV152 Vaccines in Patients with Autoimmune Rheumatic Diseases

Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Spike-antibody responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study)

Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis

The importance of cell-mediated immunity in COVID-19 -An opinion

Preprint manuscripts and servers in the era of coronavirus disease 2019

Heterogeneity: I 2 = 0%, Q = 1.65, P =

Heterogeneity: I 2 = 0%, Q = 1.33

Heterogeneity: I 2 = 0%

PubMed search strategy Number of studies #1"COVID-19" OR "SARS-CoV-2" [MeSH Terms] 98,051 #2 "inflammatory bowel diseases" OR "rheumatoid arthritis" OR "psoriasis" OR "rheumatic diseases" OR "systemic lupus erythematosus", "psoriatic arthritis", "ankylosing spondylitis", "Crohn's disease", "ulcerative colitis" OR "multiple sclerosis", "immune mediated diseases" OR "autoimmune diseases" [